Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(10%)
Results Posted
86%(6 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
4
40%
Ph phase_1
1
10%
Ph phase_3
4
40%

Phase Distribution

1

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
4(44.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(7)
Terminated(1)
Other(1)

Detailed Status

Completed7
unknown1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 24 (44.4%)
Phase 34 (44.4%)

Trials by Status

unknown110%
recruiting110%
terminated110%
completed770%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_2

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

NCT07271186
unknown

Compassionate Use of Evinacumab

NCT06500598
completedphase_3

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

NCT03409744
completedphase_3

Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

NCT05611528
completedphase_3

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

NCT04233918
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07271186Phase 2

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Recruiting
NCT06500598

Compassionate Use of Evinacumab

Unknown
NCT03409744Phase 3

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Completed
NCT05611528Phase 3

Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

Completed
NCT04233918Phase 3

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Completed
NCT04863014Phase 2

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Terminated
NCT03452228Phase 2

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Completed
NCT03175367Phase 2

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Completed
NCT03399786Phase 3

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Completed
NCT03146416Phase 1

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10